Date published: 2026-5-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

BAZ1A Activators

BAZ1A Activators are chemical compounds that either directly or indirectly enhance the chromatin remodeling function of BAZ1A. Direct activators of BAZ1A are currently not well-characterized. However, several compounds can be considered as indirect activators by influencing the epigenetic landscape and cellular signaling pathways, thus facilitating the functional activity of BAZ1A. Compounds such as VX-745 and SB203580 act as inhibitors of p38 MAPK, a kinase that may phosphorylate substrates involved in negatively regulating BAZ1A. Their inhibitory action can potentially result in the upregulation of BAZ1A's chromatin remodeling activity by relieving this negative regulation. Histone deacetylase inhibitors like SAHA can also indirectly enhance BAZ1A's function by increasing the acetylation state of histones, making chromatin more accessible for BAZ1A to act upon.

Moreover, compounds that influence DNA methylation and histone methylation such as 5-Azacytidine and Chaetocin, could enhance BAZ1A-mediated chromatin remodeling by altering epigenetic marks that affect chromatin structure and dynamics. Anacardic Acid's inhibition of HATs may create a chromatin state that is more dependent on BAZ1A's activity for transcriptional regulation. Bromodomain inhibitors like JQ1 and histone methyltransferase inhibitors like UNC1999 and GSK343 act by altering thebinding dynamics of modulatory proteins and the methylation status of histones, respectively. These alterations can decrease the density of epigenetic silencing marks on chromatin, potentially making the chromatin more open to BAZ1A-mediated remodeling.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

VX 745

209410-46-8sc-361401
sc-361401A
10 mg
50 mg
$183.00
$842.00
4
(1)

VX-745 inhibits p38 MAPK, which can reduce its phosphorylation activity on substrates that negatively regulate BAZ1A, leading to an increase in BAZ1A's chromatin remodeling activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a selective inhibitor of p38 MAPK. By inhibiting p38, the negative regulation on BAZ1A is lifted, thereby potentially enhancing BAZ1A's function in chromatin remodeling.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine, a DNA methylation inhibitor, may indirectly enhance BAZ1A's chromatin remodeling function by reducing DNA methylation, thus making the chromatin more accessible.

Anacardic Acid

16611-84-0sc-202463
sc-202463A
5 mg
25 mg
$102.00
$204.00
13
(1)

Anacardic Acid inhibits histone acetyltransferase enzymes (HATs), which may create a chromatin environment that requires BAZ1A-mediated remodeling for gene expression regulation.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

SAHA, like Trichostatin A, is a histone deacetylase inhibitor that can enhance BAZ1A-mediated chromatin remodeling by increasing histone acetylation levels.

Chaetocin

28097-03-2sc-200893
200 µg
$126.00
5
(1)

Chaetocin is a specific inhibitor of the histone methyltransferase SUV39H1, potentially facilitating BAZ1A-mediated chromatin remodeling by reducing histone H3K9 trimethylation.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

JQ1 is a BET bromodomain inhibitor, preventing the binding of BET family proteins to acetylated histones, which could enhance BAZ1A activity by allowing for increased chromatin remodeling.

UNC1999

1431612-23-5sc-475314
5 mg
$142.00
1
(0)

UNC1999 is an EZH2 inhibitor, potentially enhancing BAZ1A function by reducing histone H3K27 trimethylation and making chromatin more accessible for remodeling.

GSK343

1346704-33-3sc-397025
sc-397025A
5 mg
25 mg
$151.00
$461.00
1
(0)

GSK343 is an EZH2 inhibitor similar to UNC1999, which may enhance BAZ1A activity by decreasing H3K27me3 marks and thus promoting chromatin remodeling.